Eurofins CDMO Alphora has announced the successful development and implementation of a new AI-powered software platform designed for high-throughput salt and co-crystal screening. This innovative tool is now a core component of all solid-state screening programs at the company’s Mississauga, Ontario facility. Developed in collaboration with a local university, the machine learning-driven platform delivers highly accurate predictions for salt and co-crystal formation across active pharmaceutical ingredients (APIs) and intermediates. The new software significantly enhances the efficiency of solid form selection by reducing reliance on time-consuming trial-and-error experimentation. By leveraging advanced predictive models and a user-friendly interface, the tool enables clients to make informed, data-driven decisions earlier in the drug substance development lifecycle. This leads to faster identification of optimal solid forms, shortened development timelines, and reduced screening costs. Eurofins CDMO Alphora’s experienced Solid-State R&D team continues to provide expert guidance throughout every phase of the process—from data interpretation and experimental design to strategy execution. Beyond salt and co-crystal development, the team is equipped to address a broad range of solid-state challenges, including polymorph screening, stability assessment, and crystallization optimization. Through close collaboration with drug product and drug substance development teams, Eurofins CDMO Alphora delivers integrated solutions aimed at improving drug bioavailability, manufacturability, and overall performance. The company’s comprehensive capabilities include the development and manufacturing of small molecule APIs and HPAPIs, oral drug products, and solid-state R&D, as well as biologics development and manufacturing of monoclonal antibodies, proteins, and antibody-drug conjugates (ADCs), with sterile fill capabilities set to launch in 2026. With a facility established in 2003 and inspected by the FDA, Health Canada, and Japan’s PMDA, Eurofins CDMO Alphora employs over 250 professionals and operates as part of the global Eurofins Scientific network. As a world leader in bio-analysis, Eurofins serves over 1,000 companies across 60 countries with more than 200,000 analytical methods and over 65,000 employees in more than 950 laboratories. Eurofins Scientific S.E. shares are listed on the Euronext Paris Stock Exchange.